CLINICAL_TRIALS
trial_result
· 2014-07-01
Clinical Trial Update: Study of LY2157299 in Japanese Participants With Cancer [Phase 1]
Summary
Phase 1 study of LY2157299 (galunisertib) in Japanese participants with cancer has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Neoplasms, Neoplasm Metastasis | Phase 1 | Status: COMPLETED